BOSTON ( TheStreet) -- Fans of FDA advisory panels have a riveting week of action ahead.
Starting Tuesday morning, outside experts invited by FDA will weigh the risks and benefits of three different drugs on three consecutive days. The recommendations that emerge from these FDA advisory panels will factor into the agency's approval decisions.
On Wednesday Oct. 17, the Endocrinologic and Metabolic Drugs Advisory Committee convenes for two days of hearings to review drugs aimed at helping patients with a rare genetic disorder that causes extremely high levels of cholesterol to accumulate in their blood.The panel will review Aegerion Pharmaceuticals' (AEGR - Get Report) lomitapide on Wednesday followed on Thursday by mipomersen, a drug developed by Isis Pharmaceuticals (ISIS - Get Report) and the Genzyme unit of Sanofi (SNY - Get Report). I will be live-blogging all three FDA advisory panels with play-by-play and analysis in real time from the opening gavels all the way through the final votes.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts